Dr. Roussos Torres on the Importance of Preclinical Models in HER2+ Breast Cancer

Evanthia Roussos Torres, MD
Published: Friday, Jun 08, 2018



Evanthia Roussos Torres, MD, oncology fellow, Johns Hopkins University School of Medicine, discusses the importance of preclinical models in HER2-positive breast cancer.

A missing but necessary component of immunotherapy research in HER2-positive breast cancer is the use of preclinical data, says Roussos Torres. This could answer the question as to why there are responders and non-responders to this type of therapy. Preclinical work can help guide decisions regarding combinations and clinical trial development, Roussos adds. This could propel this area of breast cancer research forwards, she explains.

For example, the epigenetic modulator entinostat has shown signals of improvement in the immunosuppressive tumor microenvironment of mice with HER2-positive tumors, making it more amenable to checkpoint inhibition. This approach may improve response rates in HER2-positive breast cancer.


Evanthia Roussos Torres, MD, oncology fellow, Johns Hopkins University School of Medicine, discusses the importance of preclinical models in HER2-positive breast cancer.

A missing but necessary component of immunotherapy research in HER2-positive breast cancer is the use of preclinical data, says Roussos Torres. This could answer the question as to why there are responders and non-responders to this type of therapy. Preclinical work can help guide decisions regarding combinations and clinical trial development, Roussos adds. This could propel this area of breast cancer research forwards, she explains.

For example, the epigenetic modulator entinostat has shown signals of improvement in the immunosuppressive tumor microenvironment of mice with HER2-positive tumors, making it more amenable to checkpoint inhibition. This approach may improve response rates in HER2-positive breast cancer.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions & New Answers to Optimize OutcomesAug 16, 20181.5
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Publication Bottom Border
Border Publication
x